Working… Menu
Trial record 1 of 1 for:    NCT01781442
Previous Study | Return to List | Next Study

A Post Marketing Surveillance As Required By Philippine Food And Drug Administration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01781442
Recruitment Status : Withdrawn
First Posted : February 1, 2013
Last Update Posted : May 1, 2013
Information provided by (Responsible Party):

Tracking Information
First Submitted Date January 30, 2013
First Posted Date February 1, 2013
Last Update Posted Date May 1, 2013
Study Start Date June 2013
Estimated Primary Completion Date June 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: January 30, 2013)
Number of participants with Adverse Events [AEs] and Serious Adverse Events [SAEs] [ Time Frame: 2 years ]
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures
 (submitted: January 30, 2013)
No secondary outcomes [ Time Frame: No secondary outcomes ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title A Post Marketing Surveillance As Required By Philippine Food And Drug Administration
Official Title An Open Label, Non-interventional Study Of The Safety Of Temsirolimus Injection (Torisel) In The Treatment Of Advanced Renal Cell Carcinoma In Filipino Adult Patients: A Post Marketing Surveillance Study
Brief Summary This is a post marketing surveillance which determines the safety profile of the product to Filipinos. This is a FDA requirement for registration.
Detailed Description

The Philippine Food and Drug Administration requires that a post marketing surveillance study be conducted nationwide and enroll approximately 3,000 study patients. In cases where the 3,000 patients will not be met, the total sample size can be reduced to 10% of the volume of drug use during the first year of it being marketed. Final sample size will be determined after one year of marketing authorization. The decision to use Torisel must be a joint decision made by the subject and the investigator.

The investigator must discuss product information with the subject as per usual practice.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population This is a prospective observational, non-interventional study which will evaluate Torisel in Filipino adult subjects. Because the data to be collected will be under routine clinical conditions, subjects who have any of the contraindications specified in the product package insert are to be excluded. Torisel will be prescribed and administered according to the approved product information of the drug in the Philippines. Pfizer will not provide the drug for this study.
Condition Renal Cell Carcinoma
Intervention Drug: Temsirolimus

The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.

Treatment will continue until disease progression or unacceptable toxicity.

The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity.

Study Groups/Cohorts Patient Arm- temsirolimus
Intervention: Drug: Temsirolimus
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status Withdrawn
Actual Enrollment
 (submitted: April 30, 2013)
Original Estimated Enrollment
 (submitted: January 30, 2013)
Estimated Study Completion Date June 2015
Estimated Primary Completion Date June 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Subjects that will be included in this post marketing surveillance study must be consistent with the approved label indication of Torisel in the Philippines.
  • As per approved label indication, patients diagnosed with advanced renal cell carcinoma will be the ones eligible to participate in the study.
  • The decision to prescribe Torisel will necessarily precede and will be independent of the decision to enroll the patient into the study.
  • Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

  • Subjects with conditions that are contraindicated with Torisel based on the approved local product document in the Philippines will be excluded in this study. This condition includes: Patients with bilirubin >1.5 x ULN.
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT01781442
Other Study ID Numbers B1771110
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Study Director: Pfizer Call Center Pfizer
PRS Account Pfizer
Verification Date April 2013